Radiopharm Theranostics reported that RAD101 achieved 93% concordance between 18F-RAD101 PET imaging and equivocal MRI findings in a Phase 2b trial of 30 evaluable patients with suspected recurrent brain metastases, indicating substantial tumor uptake and diagnostic potential. Secondary data showed a preliminary 86% sensitivity in 14 patients with six-month follow-up, while specificity results are expected in Q4 2026 as part of the secondary endpoints. The company is planning a US Phase 3 pivotal trial in Q4 2026 to pursue a registrational pathway for RAD101, leveraging the absence of an approved PET product in the market. In a separate Phase 1 study, RAD204 demonstrated durable partial responses with at least seven months of progression-free status for the first patient and early signs of activity in a second patient, suggesting potential clinical benefit in advanced solid tumors. Overall, the reports underscore positive diagnostic and therapeutic signals for Radiopharm Theranostics, alongside continued investor disclosures and stock-related updates.